his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
The product is expected to be launched in FY25
Almost 300 million people globally have chronic hepatitis B
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
The Product will be manufactured at the company's facility in Bengaluru
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Subscribe To Our Newsletter & Stay Updated
